Technical Data
Heparanase 1 (HEP1)
Heparanase is an endo-beta-D-glucuronidase, which degrades heparan sulfate side chains of heparan sulfate proteoglycans (HSPGs) in the extracellular matrix. Heparanase plays an important role in ECM degradation, facilitating the migration and extravasation of tumor cells and inflammatory leukocytes. Upon degradation, heparanase releases growth factors and cytokines that stimulate cell proliferation and chemotaxis. Heparanase is a heterodimer comprised of a 50kD subunit harboring the active site and a 8kD subunit. It is produced as a latent 65kD precursor and proteolytically processed to its active form. Heparanase is highly expressed in myeloid leukocytes (i.e. neutrophils) in platelets and in human placenta. Human heparanase was found to be upregulated in various types of primary tumors, correlating in some cases with increased tumor invasiveness and vascularity and with poor prospective survival.

Suitable for use in Western Blot, Immunohistochemistry and Immunocytochemistry. Other applications not tested.

Recommended Dilutions:
Western Blot: 1:4000. Using lysate from 2x10e4 transfected CHO cells. 4-12% SDS-PAGE gel used; proteins were transferred to a PVDF membrane.
Immunohistochemistry: 1:40
Immunocytochemistry: 10ug/ml stained neutrophils and platelets from human blood smears.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
MabIgG2b,k5C41Affinity Purified
50ug -20CBlue IceHumanMouse
Polypeptide from the 50kD subunit of Heparanase
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, pH 7.2, 0.01% thimerosal.
Recognizes the 50kD subunit and the 65kD precursor of human Heparanase. Species Crossreactivity: mouse
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Vlodavsky, I., et al., Nat. Med. 5: 793802 (1999). 2. Vlodavsky, I. & Friedman, Y., J. Clin. Invest. 108: 341347 (2001). 3. Parish, C.R., et al., Biochem. Biophys. Acta 1471: M99M108 (2001). 4. Vlodasvsky, I., et al., Cancer Metastasis Rev. 9: 203-226 (1990). 5. Bashkin, P., et al., Biochemistry 28: 1737-1743 (1989). 6. Fairbanks, M.B., et al., J. Biol. Chem. 274: 29,587 29,590 (1999). 7. Koliopanos, A., et al., Cancer Res. 61: 46554659 (1992). 8. Gohji, K., et al., Int. J. Cancer 95: 295301 (2001).